Literature DB >> 26153760

Corrigendum: An IL-27/NFIL3 signalling axis drives Tim-3 and IL-10 expression and T-cell dysfunction.

Chen Zhu, Kaori Sakuishi, Sheng Xiao, Zhiyi Sun, Sarah Zaghouani, Guangxiang Gu, Chao Wang, Dewar J Tan, Chuan Wu, Manu Rangachari, Thomas Pertel, Hyun-Tak Jin, Rafi Ahmed, Ana C Anderson, Vijay K Kuchroo.   

Abstract

Entities:  

Year:  2015        PMID: 26153760     DOI: 10.1038/ncomms8657

Source DB:  PubMed          Journal:  Nat Commun        ISSN: 2041-1723            Impact factor:   14.919


× No keyword cloud information.
  6 in total

Review 1.  Advances in the Immunomodulatory Properties of Glycoantigens in Cancer.

Authors:  Valeria da Costa; Teresa Freire
Journal:  Cancers (Basel)       Date:  2022-04-07       Impact factor: 6.575

2.  IL-27, but not IL-35, inhibits neuroinflammation through modulating GM-CSF expression.

Authors:  Giacomo Casella; Annamaria Finardi; Hélène Descamps; Federico Colombo; Chiara Maiorino; Francesca Ruffini; Marco Patrone; Massimo Degano; Gianvito Martino; Luca Muzio; Burkhard Becher; Roberto Furlan
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379

Review 3.  Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases.

Authors:  Xin Cai; Huajie Zhan; Yuguang Ye; Jinjin Yang; Minghui Zhang; Jing Li; Yuan Zhuang
Journal:  Front Genet       Date:  2021-11-30       Impact factor: 4.599

Review 4.  Targeting N6-methyladenosine RNA modification combined with immune checkpoint Inhibitors: A new approach for cancer therapy.

Authors:  Weiwei Liu; Chaoqun Liu; Hui Wang; Lijun Xu; Jueyu Zhou; Sihua Li; Yu Cheng; Rui Zhou; Liang Zhao
Journal:  Comput Struct Biotechnol J       Date:  2022-09-15       Impact factor: 6.155

5.  On the significance of Tim-3 expression in pancreatic cancer.

Authors:  Pu-Ji Peng; Ya Li; Shuang Sun
Journal:  Saudi J Biol Sci       Date:  2017-11-09       Impact factor: 4.219

Review 6.  Alternative Checkpoints as Targets for Immunotherapy.

Authors:  Ayush Pant; Ravi Medikonda; Michael Lim
Journal:  Curr Oncol Rep       Date:  2020-11-03       Impact factor: 5.075

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.